David K. Loomis Sells 1,214 Shares of Arvinas, Inc. (NASDAQ:ARVN) Stock

Arvinas, Inc. (NASDAQ:ARVN - Get Free Report) CAO David K. Loomis sold 1,214 shares of Arvinas stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $16.75, for a total value of $20,334.50. Following the completion of the transaction, the chief accounting officer now directly owns 18,863 shares of the company's stock, valued at approximately $315,955.25. This represents a 6.05 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Arvinas Price Performance

Shares of ARVN traded up $0.44 during trading hours on Friday, hitting $17.70. The stock had a trading volume of 932,873 shares, compared to its average volume of 1,027,486. The firm has a market capitalization of $1.22 billion, a PE ratio of -6.39 and a beta of 1.88. Arvinas, Inc. has a 12 month low of $16.07 and a 12 month high of $51.51. The stock has a fifty day moving average price of $18.37 and a 200 day moving average price of $22.72.

Arvinas (NASDAQ:ARVN - Get Free Report) last announced its earnings results on Tuesday, February 11th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.07) by $0.44. Arvinas had a negative return on equity of 33.75% and a negative net margin of 75.51%. During the same period in the previous year, the business earned ($2.53) EPS. As a group, analysts anticipate that Arvinas, Inc. will post -3.81 EPS for the current fiscal year.

Institutional Trading of Arvinas

Several large investors have recently added to or reduced their stakes in ARVN. GF Fund Management CO. LTD. bought a new position in Arvinas in the fourth quarter worth approximately $28,000. KBC Group NV increased its stake in shares of Arvinas by 77.0% in the 4th quarter. KBC Group NV now owns 2,885 shares of the company's stock worth $55,000 after purchasing an additional 1,255 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in Arvinas by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,483 shares of the company's stock worth $61,000 after purchasing an additional 440 shares during the period. Quantbot Technologies LP raised its holdings in Arvinas by 147.3% in the 3rd quarter. Quantbot Technologies LP now owns 4,367 shares of the company's stock worth $108,000 after purchasing an additional 2,601 shares during the period. Finally, KLP Kapitalforvaltning AS purchased a new position in Arvinas during the fourth quarter valued at $171,000. 95.19% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the stock. Cantor Fitzgerald restated an "overweight" rating on shares of Arvinas in a research note on Friday, February 7th. Stephens initiated coverage on shares of Arvinas in a research report on Monday, November 18th. They set an "overweight" rating and a $55.00 price target for the company. Oppenheimer upped their price objective on Arvinas from $40.00 to $45.00 and gave the company an "outperform" rating in a research report on Wednesday, February 12th. Stifel Nicolaus reduced their target price on Arvinas from $63.00 to $51.00 and set a "buy" rating for the company in a report on Wednesday, February 12th. Finally, Barclays decreased their price target on Arvinas from $48.00 to $32.00 and set an "overweight" rating for the company in a research note on Monday, February 3rd. Twelve analysts have rated the stock with a buy rating, According to MarketBeat, Arvinas presently has a consensus rating of "Buy" and a consensus target price of $60.00.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.